Literature DB >> 19818080

Results of buccal mucosa grafts for repairing long bulbar urethral strictures.

Karen Fransis1, Kathy Vander Eeckt, Hendrik Van Poppel, Steven Joniau.   

Abstract

OBJECTIVES: To report the medium-term results at our institution of repairing long bulbar urethral strictures with buccal mucosal grafts. PATIENTS AND METHODS: Between January 2003 and June 2007, a buccal mucosa graft repair was used in 34 patients with recurrent bulbar strictures >2 cm. The follow-up included uroflowmetry with an ultrasonographic estimate of residual volume at 3 months, 1 year and yearly thereafter, or at the onset of obstructive voiding symptoms. A retrograde urethrogram with a voiding cysto-urethrogram was taken at 6 months. Flexible urethroscopy was used whenever a recurrent stricture was suspected. A successful outcome was defined as normal voiding with no stricture on the voiding cysto-urethrogram and no need for subsequent instrumentation.
RESULTS: The median (range) age of the patients was 55.5 (23-74) years. The mean (sd) preoperative maximum flow rate was 6.6 (2.5) mL/s with a mean (sd) residual volume of 51.7 (89.7) mL. Seven patients (21%) had had one or more previous urethral dilatations, 15 (44%) had undergone one or more internal urethrotomies and 10 (30%) received both treatments. Eight patients (24%) had previous open urethral surgery; two had no previous treatment. A dorsal onlay technique was used in 30 patients, a ventral onlay in one, a combined technique (dorsal onlay and ventral fasciocutaneous flap) in two and a two-stage buccal mucosa urethroplasty in one. The mean (sd) operative duration was 147 (36) min, and the stricture length and buccal mucosa graft length were, respectively, 3.2 (1.2) cm and 4.4 (0.6) cm. Follow-up was available in 33 patients (97%) with a mean of 23 (15.4) months. The success rate was then 94%. Both failures occurred within the first year and were managed successfully by internal urethrotomy. The mean (sd) postoperative maximum flow rate was 20 (11) mL/s with a mean (sd) residual volume of 46 (68) mL. There were no medium-term donor-site complications. Postmicturition dribbling was noted in eight patients (24%). None of the patients had de novo impotence or urinary incontinence, and to date no patient has needed a repeat open reconstruction.
CONCLUSION: Our results show that in patients with bulbar urethral strictures of >2 cm, urethroplasty using buccal mucosa is feasible, with very encouraging medium-term results. We confirm that this type of reconstruction could be considered the standard of care for bulbar strictures of >2 cm.
© 2009 THE AUTHORS. JOURNAL COMPILATION © 2009 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2009        PMID: 19818080     DOI: 10.1111/j.1464-410X.2009.08848.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

1.  Dorsal onlay buccal mucosal graft urethroplasty in female urethral stricture disease: a single-center experience.

Authors:  Apul Goel; Sagorika Paul; Divakar Dalela; Pushpalata Sankhwar; Satya Narayan Sankhwar; Vishwajeet Singh
Journal:  Int Urogynecol J       Date:  2013-10-24       Impact factor: 2.894

2.  Redo-urethroplasty: comparison of early functional results and quality of life in penile and bulbar strictures.

Authors:  Daniel Pfalzgraf; Luis Kluth; Philip Reiss; Margit Fisch; Roland Dahlem
Journal:  World J Urol       Date:  2013-10-24       Impact factor: 4.226

3.  Tissue engineering in urethral reconstruction.

Authors:  Altaf Mangera; Christopher R Chapple
Journal:  F1000 Med Rep       Date:  2010-09-08

Review 4.  Bulbar urethral stricture: How to optimise the use of buccal mucosal grafts.

Authors:  Jonathan N Warner; Eric S Wisenbaugh; Francisco E Martins
Journal:  Arab J Urol       Date:  2016-02-19

5.  Two-Stage Urethroplasty with Buccal Mucosa for Penoscrotal Hypospadias Reconstruction in a Male with a 46,XX Karyotype.

Authors:  Pieter D'hulst; Jochen Darras; Steven Joniau; Pieter Mattelaer; Linsey Winne; Diederik Ponette
Journal:  Urol Case Rep       Date:  2017-07-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.